Core Viewpoint - Clear Medical (01406.HK) reported a slight decline in revenue for the first half of the fiscal year ending September 30, 2025, due to adverse weather conditions and negative media coverage affecting business operations [1] Financial Performance - The group recorded revenue of approximately HKD 85 million, representing a decrease of less than 3% compared to the same period last year [1] Operational Challenges - The Hong Kong clinics experienced eight days of closure or significant disruption from July to September due to extreme weather conditions [1] - Negative media coverage stemming from allegations against a former director has adversely impacted the group's business in recent months [1] Strategic Developments - The company has strengthened its position in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1] Management Focus - Ongoing allegations have hindered the execution of key strategic plans and affected business operations [1] - The group is committed to efficiently completing the relevant investigations to stabilize operations and allow management to refocus on long-term strategic priorities [1] Stock Trading Status - The company's shares have been suspended from trading on the Hong Kong Stock Exchange since April 15, 2025, and will remain suspended until further notice [1]